Serum Differentially Alters the Antifungal Properties of Echinocandin Drugs
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Antifungal efficacies of the echinocandin drugs caspofungin, micafungin, and anidulafungin were reduced significantly in the presence of 50% human serum, which yielded nearly equivalent MICs or minimum effective concentrations against diverse Candida spp. and Aspergillus spp. Consistent with a direct drug interaction, serum decreased the sensitivity of glucan synthase to echinocandin drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“The echinocandin drugs caspofungin, micafungin, and anidulafungin inhibit the fungal -1,3-glucan synthase enzyme, which blocks the formation of glucan polymers, thereby disrupting fungal cell wall integrity (2).”
BackgroundPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citationEfficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2356-2360.2000 · Cited by 150 · cited 1×
“A murine candidiasis model utilizing female BALB/c mice (age, 10 to 12 weeks; weight, 20 to 25 g) was used to assess the relative in vivo efficacies of echinocandin drugs (13).”
Method
Cited by
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“Furthermore, when compared in the presence of serum (human serum decreases the potency of all echinocandins), MIC differences are minimized, suggesting that in vivo activity will be similar between echinocandins.([49,50]) Nonetheless, minor variations inMICs have been observed between the three drugs.”
BackgroundGarcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Self-citationMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Self-citationStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
“A wide range of animal and human studies indicate that echinocandin drugs are tightly bound to serum proteins CSF 80–96% [133,134], ANF more than 84% and MCF more than 99% protein bound [135].”
BackgroundInfluentialSelf-citationFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
“As previously reported (30, 32, 53), serum neutralized most potency differences between drugs observed in vitro assays.”
BackgroundResultInfluentialSelf-citationPfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
“In vitro, the agents bind to different human serum proteins and the in vitro impact of this binding varies by agent (40, 44), with caspofungin least affected.”
BackgroundCosta-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
“However, these differences in echinocandin potency are abolished in the presence of human serum and therefore cross-resistance is likely to occur in vivo [91,92].”
BackgroundIn Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196
“However, these differences in drug potency were neutralized and in vitro echinocandin crossresistance became apparent when the culture medium was mixed with 50% human serum, a finding which has been replicated elsewhere (34, 36).”
ResultSelf-citationShields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171
Arendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
“This was particularly true for anidulafungin and micafungin, in agreement with the fact that the MICs of these compounds are in general lower than that of caspofungin and much lower than the breakpoint (12, 29, 30).”
ResultSelf-citationEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140
A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus
Rocha, E. M. F., Garcia-Effron, G., Park, S., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00917-07 · Cited by 141
Self-citationAndes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00478-08 · Cited by 134
“In addition, because previous pharmacodynamic studies with other antimicrobials have demonstrated the importance of considering protein binding, we accounted for both the total (protein bound) and free (unbound) drug concentrations in these analyses (7, 9, 36, 49).”
BackgroundBeyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
Espinel-Ingroff, A. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70004-x · Cited by 105
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“Firstly, the echinocandin drugs are highly serum protein bound, which reduces their relative efficacy and shifts MICs upward [85–87].”
Self-citationCRS–MIS in Candida glabrata: sphingolipids modulate echinocandin–Fks interaction
Healey, K. R., Katiyar, S. K., Raj, S., & Edlind, T. D. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08194.x · Cited by 79
Shields, R. K., Nguyen, M. H., Du, C., Press, E., Cheng, S., & Clancy, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-10 · Cited by 65
Arendrup, M. C., Rodriguez-Tudela, J.-L., Park, S., Garcia-Effron, G., Delmas, G., Cuenca-Estrella, M., Gomez-Lopez, A., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01364-10 · Cited by 57
“Earlier studies demonstrated that the addition of human serum to MIC assay media neutralizes differences between the in vitro properties of the echinocandin drugs (24, 26, 38).”
BackgroundSelf-citationRepurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Kim, K., Zilbermintz, L., & Martchenko, M. (2015) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-015-0090-4 · Cited by 48
“inhibit the activity of known antifungal drugs [8].”
BackgroundKawai, A., Yamagishi, Y., & Mikamo, H. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.05.007 · Cited by 23
“Factors such as protein binding in human serum might also influence the MIC for MFG, since serum shifts the activity of MFG in in vitro susceptibility tests on Candida spp [27,28].”
BackgroundJia, Y., Tang, R.-J., Wang, L., Zhang, X., Wang, Y., Jia, X.-M., & Jiang, Y.-Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048369 · Cited by 19
“Previous studies have demonstrated that biological fluids such as serum can have profound effects on antifungal susceptibilities [43,44,45,46].”
BackgroundDrug susceptibility of matrix‐encapsulated Candida albicans nano‐biofilms
Srinivasan, A., Gupta, C. M., Agrawal, C. M., Leung, K. P., Lopez‐Ribot, J. L., & Ramasubramanian, A. K. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25120 · Cited by 11
“A similar or even higher increase in IC50 in the presence of serum has been reported for other echinocandin drugs, micafungin and anidulafungin (Paderu et al. 2007).”
Background
Metadata
- Authors
- Paderu, P., Garcia-Effron, G., Balashov, S., Delmas, G., Park, S., & Perlin, D. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-06
- Volume
- 51
- Issue
- 6
- Pages
- 2253-2256
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2122363207
- Cited by
- 111
- References
- 3
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.